– Peculiar shares anticipated to begin buying and selling on Nasdaq on April 20, 2026 following alternate of all American Depositary Shares (ADSs)
– ADS holders will obtain one abnormal share listed on Nasdaq for every ADS held
– Simplified itemizing construction supposed to allow enhanced depth and breadth of possession
COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) at the moment introduced that it plans to record its abnormal shares straight on Nasdaq, efficient on the opening of buying and selling on April 20, 2026.
As a part of the transition to a direct itemizing of abnormal shares on The Nasdaq International Choose Market, all excellent ADSs shall be exchanged for abnormal shares. Every ADS presently eligible for buying and selling shall be exchanged for one abnormal share, which shall be listed and begin buying and selling on The Nasdaq International Choose Market underneath the Firm’s present ticker image “ASND” on April 20, 2026.
More Read
“As we transform into a leading global biopharma company, we believe a direct listing of our ordinary shares will broaden access to global investment in Ascendis,” stated Scott T. Smith, Chief Monetary Officer of Ascendis Pharma. “In addition, we believe a direct listing may also facilitate inclusion in certain equity indexes, which could result in further enhanced institutional ownership and trading liquidity for ASND shares.”
About Ascendis Pharma A/SAscendis Pharma is a world biopharmaceutical firm centered on making use of our revolutionary TransCon know-how platform to make a significant distinction for sufferers. Guided by our core values of Sufferers, Science, and Ardour, and following our algorithm for product innovation, we apply TransCon to develop new therapies that exhibit best-in-class potential to handle unmet medical wants. Ascendis is headquartered in Copenhagen, Denmark, and has extra services in Europe and the USA. Please go to ascendispharma.com to be taught extra.
Ahead-Trying Statements This press launch comprises forward-looking statements that contain substantial dangers and uncertainties. All statements, aside from statements of historic info, included on this press launch relating to Ascendis’ future operations, plans and aims of administration are forward-looking statements inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. Examples of such statements embrace, however are usually not restricted to, statements referring to (i) the contemplated timing and implementation of the alternate of ADSs for abnormal shares, (ii) the contemplated itemizing and buying and selling of abnormal shares on The Nasdaq International Choose Market, and (iii) the anticipated advantages of the direct itemizing of abnormal shares. Ascendis could not truly obtain the plans, perform the intentions or meet the expectations or projections disclosed within the forward-looking statements and you shouldn’t place undue reliance on these forward-looking statements. Precise outcomes or occasions might differ materially from the plans, intentions, expectations and projections disclosed within the forward-looking statements. Varied necessary elements might trigger precise outcomes or occasions to vary materially from the forward-looking statements that Ascendis makes, together with the next: dangers that the alternate of ADSs for abnormal shares is probably not accomplished on the anticipated timeline or in any respect; dangers associated to the eligibility of the abnormal shares for clearance and holding in The Depository Belief Firm system; the chance that abnormal shares is probably not accepted for itemizing on The Nasdaq International Choose Market, or that itemizing could also be delayed or topic to circumstances; dangers that buying and selling in abnormal shares on Nasdaq could also be much less liquid or end in completely different buying and selling dynamics than buying and selling in ADSs; potential adversarial tax penalties to ADS holders in reference to the alternate of ADSs for abnormal shares; and dangers associated to the influence of the alternate of ADSs for abnormal shares on the Firm’s different excellent securities. For an extra description of the dangers and uncertainties that would trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to Ascendis’ enterprise generally, see Ascendis’ Annual Report on Type 20-F filed with the U.S. Securities and Trade Fee (SEC) on February 11, 2026, and Ascendis’ different future reviews filed with, or submitted to, the SEC. Ahead-looking statements don’t mirror the potential influence of any future licensing, collaborations, acquisitions, mergers, tendencies, joint ventures, or investments that Ascendis could enter into or make. Ascendis doesn’t assume any obligation to replace any forward-looking statements, besides as required by legislation.
Ascendis, Ascendis Pharma, the Ascendis Pharma emblem, and TransCon are logos owned by the Ascendis Pharma group.© April 2026 Ascendis Pharma A/S.
Investor Contacts:Media Contact:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875
